Evidence map›Paper›PMID 42782560›Full record

ArticleJournal of neuro-oncology2026

Prognostic impact of blood group O in MGMT-methylated glioblastoma patients receiving radiochemotherapy with temozolomide and lomustine.

Julia Scheuble, Thomas Zeyen, Matthias Schneider, Anna-Laura Potthoff, Niklas Schäfer, Lea Lex, Lea L Friker, Alexander Radbruch, Julian P Layer, Eleni Gkika and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julia ScheubleDepartment of Neuro-Oncology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Thomas ZeyenDepartment of Neuro-Oncology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Matthias SchneiderBrain Tumor Translational Research Group, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Anna-Laura PotthoffBrain Tumor Translational Research Group, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Niklas SchäferDepartment of Neuro-Oncology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Lea LexDepartment of Neuro-Oncology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Lea L FrikerBrain Tumor Translational Research Group, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Alexander RadbruchDepartment of Neuroradiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Julian P LayerBrain Tumor Translational Research Group, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Eleni GkikaDepartment of Radiation Therapy and Radiooncology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Hartmut VatterBrain Tumor Translational Research Group, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Ulrich HerrlingerDepartment of Neuro-Oncology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Johannes WellerDepartment of Neuro-Oncology, University Hospital Bonn, University of Bonn, Venusberg Campus 1, 53127, Bonn, Germany. johannes.weller@ukbonn.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBlood group O has recently been associated with improved survival in patients with MGMT-methylated glioblastoma. However, whether this association persists in patients treated with intensified first-line radiochemotherapy according to the CeTeG/NOA-09 regimen remains unclear. We aimed to validate the prognostic impact of ABO blood group in an independent cohort of patients with MGMT-methylated, IDH-wildtype glioblastoma uniformly treated with CCNU/temozolomide (CCNU/TMZ).

methodsWe performed a retrospective single-center cohort study including adult patients with newly diagnosed MGMT-methylated, IDH-wildtype glioblastoma treated according to the CeTeG/NOA-09 protocol between 2008 and 2023. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier estimates, log-rank tests, and multivariable Cox proportional hazards models adjusted for age, extent of resection, and Karnofsky Performance Status.

resultsSixty-one patients were included, of whom 24 (39.3%) had blood group O and 37 (60.7%) had non-O blood groups. Blood group O was associated with longer OS (median 42.1 vs. 23.7 months; log-rank p = 0.04) and a trend toward longer PFS (median 21.8 vs. 17.5 months; log-rank p = 0.10). After multivariable adjustment, non-O blood groups remained independently associated with shorter PFS (HR 1.86, 95% CI 1.04-3.34; p = 0.037) and OS (HR 2.29, 95% CI 1.16-4.52; p = 0.017).

conclusionBlood group O remained associated with improved progression-free and overall survival in patients with MGMT-methylated, IDH-wildtype glioblastoma treated according to the CeTeG/NOA-09 regimen. These findings support an association between blood group O and improved survival outcomes and warrant further investigation of its biological and clinical relevance in glioblastoma.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsChemoradiotherapyDNA Modification MethylasesDNA Repair EnzymesGlioblastomaTumor Suppressor ProteinsAdultAgedDNA MethylationFemaleFollow-Up StudiesHumansLomustineMaleMiddle AgedDNA Modification MethylasesDNA Repair EnzymesLomustineMGMT protein, humanTemozolomideTumor Suppressor ProteinsABO blood groupGlioblastomaLomustineMGMT promoter methylationTemozolomide

Identifiers

PMID42782560
PMCPMC13612688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.